Aptinyx Reports Results of NYX-2925 in P-IIb Study for the Treatment of Painful Diabetic Peripheral Neuropathy
Shots:
- The P-IIb study evaluates the efficacy & safety of NYX-2925 (50mg, qd) vs PBO in 229 patients with painful DPN
- The trial failed to meet its 1EPs i.e., the therapy showed an improvement in average daily pain scores but separation from PBO was not observed in this study & in other EPs. The therapy was well tolerated & no concerning safety issues were observed
- In clinical studies, the therapy showed an activity that affects central, supraspinal pain processing resulting in alleviation of pain & other symptoms associated with specific chronic pain conditions & has favorable safety & tolerability profile. The results from a P-IIb study of NYX-2925 for fibromyalgia are expected in early to mid-Q3’22
Ref: Businesswire | Image: Aptinyx
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
